FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MUELLER PETER							2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								all applic			son(s) to Iss 10% Ov Other (s	vner
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET						3. Date of Earliest Transaction (Month/Day/Year) 07/15/2008								X Officer (greeting below) EVP Drug Innov.& Realiz, CSO					
(Street) CAMBRIDGE MA 02139						4. If Amendment, Date of Original Filed (Month/Day/Year)								Indiv ne) X	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(3			lon Dori	votivo			ioo A	auiro	-d D	ionocod a	of or B	noficia	.II. r)wnoo	<u> </u>			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					tion	2A. D Exec if any	eeme	ed	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amount		int of es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price			tion(s)			(Instr. 4)
Common Stock 07/15/20)8			M		2,400	A	\$9.07	7 8		3,790		D	
Common Stock 07/15/20					2008	08			S ⁽¹⁾		1,200	D	\$32.590	3)(4) 87		,590		D	
Common Stock 07/15/20					2008)8			S ⁽¹⁾		1,200	D	\$32.21(3)(4)		86,390			D	
Common Stock															3,	460		I	401(k)
		Т	able II								posed of , converti			y Oı	wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Executi if any	A. Deemed xecution Date, any Month/Day/Year)		ction Instr.			6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title at Amount Securitie Underlyi Derivativ (Instr. 3 a	of s ng e Security	De Se	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						
Stock	\$9.07	07/15/2008			м			2 400	(5))	12/10/2013	Common	2 400		\$0	12 000	, I	D	1

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$32.59 (range \$32.38 to \$33.10).
- 3. Open market sales reported on this line occurred at a weighted average price of \$32.21 (range \$32.08 to \$32.33).
- 4. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 5. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-In-Fact

07/17/2008

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.